Illumina, Inc. (ETR: ILU)

Market Cap	20.71B
Revenue (ttm)	3.93B
Net Income (ttm)	-1.42B
Shares Out	n/a
EPS (ttm)	-8.94
PE Ratio	n/a
Forward PE	n/a
Dividend	2.89 (2.14%)
Ex-Dividend Date	Jun 25, 2024

Volume	11
Open	129.22
Previous Close	134.52
Day's Range	129.22 - 130.40
52-Week Range	93.00 - 150.56
Beta	1.13
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 7, 2025

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 10,640
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ILU

Financial Performance

In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.

Financial numbers in USD